Meeting
2020 Gastrointestinal Cancers Symposium
NSABP FR-2: Phase II study of durvalumab following neoadjuvant chemoRT in stage II-IV rectal cancer.
Authors
Thomas J. George
NSABP Foundation, Inc., and The University of Florida Health Cancer Center, Gainesville, FL
Thomas J. George , Greg Yothers , Samuel A. Jacobs , Gene Grant Finley , Hiral D. Parekh , Timothy David Moore , Bassam Nabih Maalouf , John C. Krauss , Melvin Deutsch , James J. Lee , Carmen Joseph Allegra , Norman Wolmark
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Anal and Colorectal Cancer
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03102047
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr TPS264)
Abstract #
TPS264
Poster Bd #
M20
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
NSABP FR-2: Phase II study of durvalumab following neoadjuvant chemoRT in stage II-IV rectal cancer.
First Author: Thomas J. George
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Phase II study of durvalumab following neoadjuvant chemoRT in operable rectal cancer: NSABP FR-2.
First Author: Thomas J. George
Poster
2018 ASCO Annual Meeting
NSABP FR-2: Phase II study of durvalumab following neoadjuvant chemotherapy (NAC) in stage II-IV rectal cancer.
First Author: Thomas J. George Jr.
Poster
2020 ASCO Virtual Scientific Program
Phase II study of durvalumab plus total neoadjuvant therapy (TNT) in locally advanced rectal cancer: The GEMCAD-1703 DUREC trial.
First Author: Jaume Capdevila